Shearman & Sterling hosted a roundtable discussion on the latest policy trends and their impact on M&A and Corporate Governance within the Life Sciences industry.

Keynote speakers included: 

• Jim Greenwood, President and CEO of the Biotechnology Innovation Organization (BIO)
  
  James C. Greenwood is President and CEO of the Biotechnology Innovation Organization (BIO) in Washington, D.C. BIO represents 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 countries worldwide. Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives from 1993 to 2005 and chaired the House Energy and Commerce oversight subcommittee.

• Steven Davidoff Solomon, Professor of Law at U.C. Berkeley School of Law and Faculty Co-Director of the Berkeley Center for Law and Business
  
  Professor Davidoff Solomon is a leading scholar on corporate law and has written a weekly column for The New York Times as The Deal Professor, which primarily focuses on corporate issues. The National Association of Corporate Directors has thrice named him as one of the 100 most influential people in the United States corporate boardroom community.

The panel was joined by Shearman & Sterling partners Doreen Lilienfeld (New York-Compensation, Governance & ERISA) and Michael Dorf (New York-Mergers & Acquisitions).